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Several neurodegenerative disorders are characterized by the accumulation of proteinaceous inclu-
sions in the central nervous system. These inclusions are frequently composed of a mixture of aggre-
gation-prone proteins. Here, we used a bimolecular ﬂuorescence complementation assay to study
the initial steps of the co-aggregation of huntingtin (Htt) and a-synuclein (a-syn), two aggrega-
tion-prone proteins involved in Huntington’s disease (HD) and Parkinson’s disease (PD), respec-
tively. We found that Htt (exon 1) oligomerized with a-syn and sequestered it in the cytosol. In
turn, a-syn increased the number of cells displaying aggregates, decreased the number of aggregates
per cell and increased the average size of the aggregates. Our results support the idea that co-aggre-
gation of aggregation-prone proteins can contribute to the histopathology of neurodegenerative
disorders.
Structured summary of protein interactions:
Htt and Htt physically interact by bimolecular ﬂuorescence complementation (View interaction)
alpha-syn and Htt physically interact by bimolecular ﬂuorescence complementation (View interaction)
alpha-syn and alpha-syn physically interact by comigration in non-denaturing gel electrophoresis (View
interaction)
Htt and Htt physically interact by comigration in non-denaturing gel electrophoresis (View interaction)
alpha-syn and Htt colocalize by ﬂuorescence microscopy (View Interaction: 1, 2)
alpha-syn and alpha-syn physically interact by bimolecular ﬂuorescence complementation (View inter-
action)
Htt and alpha-syn physically interact by comigration in non-denaturing gel electrophoresis (View inter-
action)
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The presence of amyloid-like proteinaceous inclusions is the
common histopathological hallmark of a large group of human
diseases known as protein misfolding disorders. Neurodegenera-
tive disorders such as Alzheimer’s (AD), Parkinson’s (PD) or
Huntington’s disease (HD) belong to this group of pathologies.
The speciﬁc location and composition of protein aggregates are
characteristic of each disorder. For example, while PD aggregateschemical Societies. Published by E
n; HD, Huntington’s disease;
FC, bimolecular ﬂuorescence
generation and Restaurative
, 37073 Gottingen, Germany.
.(Lewy Bodies) consist primarily of a-synuclein (a-syn) protein,
the main component of HD aggregates is a very large protein
named huntingtin (Htt). The areas of the brain that are initially af-
fected by these aggregates and the clinical symptoms are also dif-
ferent among the different neurodegenerative disorders [Reviewed
in [1–3]]. However, growing evidence indicates that the differences
between neurodegenerative disorders are not as clear as initially
thought and that there is substantial overlap among them.
Neurodegenerative disorders often show mixed features at all
levels [4]. Patients with movement disorders, such as PD and HD,
frequently develop dementia in intermediate or late stages [5].
Conversely, patients with a primary diagnosis of dementia can
show PD-like motor symptoms [6]. The differences between disor-
ders are even more blurred at the cellular and molecular level. For
example, a-syn was originally identiﬁed as the precursor of the
major non-amyloid component of AD plaques [7]. The depositionlsevier B.V. All rights reserved.
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characterized as tau-associated pathologies (tauopathies), such as
AD, Down syndrome, progressive supranuclear palsy, parkinson-
ism dementia complex of Guam and frontotemporal dementia
[8–11]. Conversely, deposition of tau has been observed in patients
with familial and sporadic PD, sporadic dementia with Lewy bodies
and multiple system atrophy and animal models of some of these
disorders [12–18].
The co-occurrence of aggregation-prone proteins might have
important pathological consequences. For example, Tau enhances
a-syn aggregation in vitro [15] and in cell cultures [19]. Likewise,
a-syn can promote amyloid b peptide aggregation in vivo [20]
and, triple transgenic mice for amyloid b peptide, tau and a-syn
show an enhancement of all three pathologies [21].
A decade ago, two independent groups showed that Htt inclu-
sions in patients and mouse models of HD are positive for a-syn
[22] and that over-expression of a-syn in human cells promotes
Htt aggregation [23]. To the best of our knowledge, these are the
only reports on the interplay between these two aggregation-
prone proteins. In the present work we employed the bimolecular
ﬂuorescent complementation (BiFC) assays we recently developed
[24,25] to visualize and study further the interaction between Htt
and a-syn in living human cells.
2. Materials and methods
2.1. Yeast strains, plasmids and growth conditions
We used Saccharomyces cerevisiaeW303 strain (MATa can1-100
his3-11, 15 leu2-3, 112 trp1-1 ura3-1 ade2-1) under standard growth
conditions. Cells were transformed with lithium acetate with
p426GPD-a-synuclein-YFP and p423GPD-huntingtin-CFP con-
structs [26,27]. Cells were maintained in SD-URA-HIS solid med-
ium and were grown up to mid log phase for epiﬂuorescence
microscopy analysis.
2.2. Cell cultures and plasmids
Human H4 glioma cells (ATCC HTB-148, LGC Standards,
Barcelona, Spain) were maintained and seeded as previously de-
scribed [24]. The development of wild-type (25Q) and mutant
(103Q) Htt-Venus BiFC plasmids was described in detail elsewhere
[24]. a-Synuclein-Venus BiFC plasmids were a kind gift of Dr.
Pamela J. McLean (Department of Neurology, Alzheimer’s DiseaseFig. 1. a-Syn co-localizes with Htt aggregates. (A) Yeast cells were co-transfected with a-
bar 2 lm. (B) H4 human glioma cells co-transfected with 103QHtt exon 1 tagged with f
localization of a-syn and mutant Htt in aggregates (white arrowheads). Scale bar 20 lmResearch Unit, Massachusetts General Hospital, MA, USA). Cells
were transfected with the different combinations of plasmids using
Fugene 6 transfection reagent (Roche diagnostics, Mannheim, Ger-
many) 16–24 h after seeding. Samples were collected or analyzed
24 h after transfection unless otherwise indicated. Toxicity assays
were carried out as described previously [24].
2.3. Flow cytometry
Cells were collected by trypsinization (5 min at 37 C), washed
once with PBS, and ﬁxed in 1% (w/v) paraformaldehyde in PBS
for 10 min at room temperature. Samples were analyzed by means
of a FACSCalibur ﬂow cytometer (Beckton Dickinson, Franklin
Lakes, NJ, USA). Ten thousand cells were analyzed per group.
Graphics and data analysis were carried out by means of the FlowJo
software (Tree Star Inc., Ahsland, OR, USA).
2.4. Immunocytochemistry and microscopy
Living cells were analyzed directly by wideﬁeld ﬂuorescence
microscopy (BiFC experiments, Figs. 2 and 3) or processed for
immunocytochemistry as described previously [28] (Fig. 1). The
following antibodies were used: Htt (1:100, Millipore, Billerica,
MA, USA), a-syn (1:100, Cell Signaling, Danvers, MA, USA), and
Alexa ﬂuor 488- and 568-conjugated secondary antibodies
(1:1000, Invitrogen Technologies, Carlsbad, CA, USA).
Cells were visualized, and pictures were taken, by means of an
Axiovert 200 M wideﬁeld ﬂuorescence microscope equipped with
a CCD camera (Carl Zeiss MicroImaging GmbH, Germany). Images
were analyzed and prepared for publication by means of the
ImageJ free software (http://rsbweb.nih.gov/ij/).
2.5. Immunoblotting
Proteins were extracted by scrapping cells directly from the
plates into lysis buffer. For denaturalizing conditions, the lysis buf-
fer was 0.1% Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.4 and a
protease inhibitor cocktail tablet (Roche diagnostics, Mannheim,
Germany). For native conditions, the lysis buffer was 50 mM
Tris–HCl pH 7.4, 175 mM NaCl, 5 mM EDTA and a protease inhibi-
tor cocktail tablet (Roche diagnostics, Mannheim, Germany). Cells
were then sonicated and centrifuged at 10 000g for 10 min at
4 C. Supernatants were collected and the protein concentration
was quantiﬁed by the Bradford assay (Bio-rad, Hercules, CA,syn-YFP (in yellow) and wild type (25Q) or mutant (103Q) Htt exon 1 (in blue). Scale
ull length EGFP (in green) and non-tagged a-syn (in red). In both cases, there is co-
.
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acrylamide SDS–PAGE for denaturing conditions, or on miniProte-
an TGX 4–20% acrylamide gradient precast gels (Bio-rad, Hercules,
CA, USA) for native conditions. Proteins were transferred to PVDF
membranes for blotting with antibodies against Htt (1:1000, Milli-
pore, Billerica, MA, USA), a-syn (1:1000, BD Biosciences, San Jose,
CA, USA) and GAPDH (1:30000, Ambion, Austin, TX, USA) as indi-
cated in each case. Immunoblots were developed with enhanced
chemiluminescence reagents (Millipore, Billerica, MA, USA) and
exposition to autorradiographic ﬁlm.
2.6. Filter retardation assays
Cell lysates were obtained in native conditions, as described
above, and 100 lg of protein extracts were mixed with a 10% (w/
v) SDS solution to a ﬁnal SDS concentration of 1% (w/v). ProteinFig. 2. a-Syn oligomerizes and co-aggregates with Htt. (A) BiFC constructs. Both a-syn an
the V1-Linkr-a-syn construct, where a-syn was located in the C-terminus of the Venus 1
order to improve the ﬂexibility of the fusion protein and allow a-syn to interact with a-s
report. (B) There is production of ﬂuorescence with the different combinations of BiFC co
emit ﬂuorescence, as exempliﬁed by the 25QHtt-V1 construct. The a-syn pair of BiFC con
of BiFC constructs typically shows homogeneous ﬂuorescence in the cytosol, but rarely in
type or mutant Htt-V1 constructs are combined with the a-syn-V2 construct, the pattern
immunoblotting of total protein extracts under denaturing and native conditions. Cells tra
SDS-insoluble aggregates; cells transfected with the 103QHtt pair showed production o
103QHtt/a-syn pair showed a mixed phenotype between the 103QHtt pair and the a-sy
under denaturing conditions (SDS–PAGE).samples were loaded on a dot blotting apparatus and ﬁltered
through cellulose acetate membranes (0.22 lm pore; GE Water &
Process Technologies, Fairﬁeld, CT, USA) by vacuum. Cellulose ace-
tate membranes retain aggregates that are not soluble in SDS and
larger than 0.22 lm. After ﬁltration, slots were washed twice with
PBS plus 1% SDS. Detection of Htt was done by immunoblotting as
described above.
2.7. Statistics
All graphs show the average ± standard deviation of at least
three independent experiments. Statistical analyses were carried
out by means of the SigmaPlot 11.0 software (Systat Software
Inc., Chicago, IL, USA). Results were analyzed by means of a one-
way ANOVA followed by a Tukey post-hoc test. Statistical signiﬁ-
cance was accepted only when P < 0.05.d Htt exon 1 were located in the N-termini of the Venus halves, with the exception of
half. This construct also had a serine/glycine linker between Venus 1 and a-syn in
yn-V2. Constructs for both wild-type (25Q) and mutant (103Q) Htt were used in this
nstructs, suggesting that a-syn/Htt dimers were generated. Single constructs do not
structs shows homogeneous ﬂuorescence in all cell compartments. The 25Q Htt pair
the nucleus. The 103Q Htt pair of constructs shows cytosolic aggregates. When wild
resembles the corresponding Htt BiFC pairs. Scale bar, 20 lm. C, Filter trap assay and
nsfected with the 25QHtt or the a-syn BiFC pairs showed oligomeric species but not
f both oligomeric species and insoluble aggregates; and cells transfected with the
n pair. The expression levels of each construct were evaluated by immunoblotting
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3.1. Htt co-aggregates with a-syn and sequesters it in the cytosol
a-Syn co-localizes with Htt aggregates in HD patients and ani-
mal models [22], and we conﬁrmed this observation in both yeast
cells and H4 human neuroglioma cells in culture (Fig. 1). In order to
test whether these two proteins oligomerize in living cells in cul-
ture, we used a Venus-based BiFC assay. In this assay, Htt exon 1
and a-syn were fused to two non-ﬂuorescent halves of the Venus
ﬂuorescent protein (Fig. 2A). Heterodimerization of these proteins
would bring Venus halves together and reconstitute the functional
ﬂuorophore. This assay enables the differentiation of monomers
from dimers and oligomers, and these soluble species from larger
aggregates. Dimers and oligomers are undistinguishable by epi-
ﬂuorescence microscopy and, therefore, for the sake of simplicity,Fig. 3. a-Syn is a modiﬁer of Htt aggregation. A, Representative picture of cells transfec
B-D, Co-expression of a-syn with mutant Htt increases the percentage of cells showing
percentage of aggregates larger than 1 lm at the expense of aggregates smaller than 1 l
a-syn does not modify the toxicity of mutant Htt. ⁄Signiﬁcant vs the 25QHtt pair, P < 0.we use the term ‘‘oligomer’’ to refer to both species of soluble
aggregates.
Co-transfection of 25Q or 103Q Htt-V1 BiFC constructs with the
a-syn-V2 BiFC construct produced ﬂuorescence, demonstrating a
direct interaction between the two proteins (Fig. 2B). Cells
transfected with a pair of a-syn-Venus BiFC plasmids showed both
cytosolic and nuclear ﬂuorescence, as observed previously with
a-syn-EGFP BiFC plasmids [25]. Fluorescence was homogeneous,
suggesting the presence of a-syn oligomeric species throughout
the cell, and no large inclusions of a-syn were observed. On the
other hand, cells transfected with pairs of wild-type or mutant
Htt-Venus BiFC constructs showed generally cytoplasmic ﬂuores-
cence and the occurrence of large inclusions (Fig. 2B) [24]. When
Htt-V1 and a-syn-V2 BiFC constructs were combined, Htt clearly
oligomerized and aggregated with a-syn. Htt abolished the nuclear
ﬂuorescence that is typical of a-syn BiFC systems, stronglyted with the 103QHtt/103QHtt or 103QHtt/a-syn combinations of BiFC constructs.
aggregates (B), decreases the number of aggregates per cell (C), and increases the
m (D). E, The 103Q Htt pair is more toxic than the 25Q Htt pair, and the presence of
05; #Signiﬁcant vs the 103QHtt pair, P < 0.05. Scale bar, 20 lm.
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strong nuclear export signal in the ﬁrst 17 amino acids of its exon 1
[29], which is responsible for the normal cytosolic location of Htt
and could explain its ability to sequester a-syn in the cytosol.
While mutant Htt forms oligomeric species of variable size and
large SDS-insoluble aggregates, wild type Htt generates single-size
oligomeric species and no SDS-insoluble aggregates (Fig. 2C) [24].
The a-syn-Venus BiFC system produces a-syn oligomeric species
in native conditions, but it does not show large insoluble aggre-
gates in ﬁlter trap assays (data not shown). The combination of
mutant Htt with a-syn showed a mixed pattern of aggregation, be-
tween Htt and a-syn patterns. In particular, there is a decrease in
the levels of large Htt SDS-insoluble species versus the mutant
Htt BiFC pair, and a decrease in the amount of a-syn oligomers ver-
sus the a-syn BiFC pair (Fig. 2C).
In summary, these results strongly suggest that Htt exon 1 and
a-syn interact, form hetero-oligomeric species, and co-aggregate
in large inclusions. Theyalso indicate thatHttexon1anda-synmod-
ify their respective patterns of aggregation in each other’s presence.
3.2. a-Syn is a modiﬁer of Htt aggregation
a-Syn was previously reported to enhance Htt aggregation in
cells in culture [23]. In order to conﬁrm this observation in our cell
system, we transfected H4 cells with 103QHtt/103QHtt or
103QHtt/a-syn pairs of BiFC constructs and quantiﬁed the number
of cells displaying aggregates, as well as the number and size of
these aggregates. Fig. 3A shows a representative image of these
cells. The presence of aggregates was signiﬁcantly more frequent
in cells transfected with a pair of mutant Htt BiFC constructs than
in cells transfected with the wild-type counterparts (Fig. 2B). Co-
transfection of cells with mutant Htt-V1 and a-syn-V2 signiﬁcantly
increased the percentage of cells showing intracellular inclusions
(Fig. 3B), but it decreased the number of inclusions per cell to
approximately a half (Fig. 3C). The percentage of aggregates smal-
ler than 1 lm decreased signiﬁcantly (Fig. 3D). This decrease was
accompanied by an increase in the percentage of aggregates larger
than 1 lm, especially in those aggregates larger than 3 lm
(Fig. 3D). The increase in the average size of aggregates was asso-
ciated with a decrease in the number of aggregates per cell, sug-
gesting that a-syn promotes the aggregation of small and
medium-size aggregates into larger aggregates. These results indi-
cate that a-syn is a modiﬁer of Htt aggregation.
Whether the size, morphology and solubility of pathologic pro-
tein aggregates are related with their toxicity is still a matter of in-
tense debate [1–3]. Furthermore, synergistic co-aggregation of
proteins is frequently associated with an increase in their toxicity
[21]. In order to investigate if the modulation of Htt aggregation by
a-syn is correlated to changes in Htt toxicity, we analyzed the tox-
icity of different combinations of BiFC constructs (Fig. 3E). The
mutant Htt-Venus BiFC pair is more toxic than the wild-type pair,
as previously described [24]. The toxicity of mutant Htt was not
altered by the presence of a-syn (Fig. 3E).
In the present report, we present evidence indicating that a-syn
and Htt interact and co-aggregate. Our data also demonstrate that,
in our cell system, a-syn and Htt modify each other’s aggregation
pattern. Htt sequesters a-syn in the cytosol, makes it aggregate
(Fig. 2B), and decreases the levels of a-syn oligomeric species
(Fig. 2C). Conversely, a-syn promotes the generation of fewer lar-
ger inclusions (Fig. 3A), while increasing their solubility in SDS
and keeping the levels of Htt oligomeric species constant
(Fig. 2C). Growing evidence indicates that aggregation-prone pro-
teins can co-aggregate and have a synergistic neurotoxic effect in
different protein misfolding disorders, including many neurode-
generative disorders [7,13,20,21,30]. Previous reports showed that
a-syn co-localize with Htt in HD patients and mouse models of thedisorder [23], and that a-syn potentiates Htt aggregation in cells in
culture [22]. In spite of the potential interest for the treatment and
understanding of HD and PD, we are not aware of other published
studies on the interplay between these two aggregation-prone pro-
teins. Our results are consistent with these reports and provide an
insight into the consequences of the interaction between a-syn
and Htt at a cellular and molecular level.
Acknowledgements
TFO is supported by an EMBO Installation Grant, a Marie Curie
International Reintegration Grant (Neurofold), and Fundação para a
Ciência e Tecnologia, Portugal. FH is supported by a fellowship
from the Fundação para a Ciência e a Tecnologia (SFRH/BPD/
63530/2009).
References
[1] Agorogiannis, E.I., Agorogiannis, G.I., Papadimitriou, A. and Hadjigeorgiou,
G.M. (2004) Protein misfolding in neurodegenerative diseases. Neuropathol.
Appl. Neurobiol. 30, 215–224.
[2] Rochet, J.C. (2007) Novel therapeutic strategies for the treatment of protein-
misfolding diseases. Expert Rev. Mol. Med. 9, 1–34.
[3] Tarawneh, R. and Galvin, J.E. (2010) Potential future neuroprotective therapies
for neurodegenerative disorders and stroke. Clin. Geriatr. Med. 26, 125–147.
[4] Lippa, C.F., Duda, J.E., Grossman, M., Hurtig, H.I., Aarsland, D., Boeve, B.F.,
Brooks, D.J., Dickson, D.W., Dubois, B., Emre, M., Fahn, S., Farmer, J.M., Galasko,
D., Galvin, J.E., Goetz, C.G., Growdon, J.H., Gwinn-Hardy, K.A., Hardy, J.,
Heutink, P., Iwatsubo, T., Kosaka, K., Lee, V.M., Leverenz, J.B., Masliah, E.,
McKeith, I.G., Nussbaum, R.L., Olanow, C.W., Ravina, B.M., Singleton, A.B.,
Tanner, C.M., Trojanowski, J.Q. and Wszolek, Z.K. (2007) DLB and PDD
boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
Neurology 68, 812–819.
[5] Perry, R.J. and Hodges, J.R. (1996) Spectrum of memory dysfunction in
degenerative disease. Curr. Opin. Neurol. 9, 281–285.
[6] Tsolaki, M., Kokarida, K., Iakovidou, V., Stilopoulos, E., Meimaris, J. and Kazis, A.
(2001) Extrapyramidal symptoms and signs in Alzheimer’s disease: prevalence
and correlation with the ﬁrst symptom. Am. J. Alzheimers Dis. Other Demen.
16, 268–278.
[7] Yoshimoto, M., Iwai, A., Kang, D., Otero, D.A., Xia, Y. and Saitoh, T. (1995) NACP,
the precursor protein of the non-amyloid beta/A4 protein (A beta) component
of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.
Proc. Natl. Acad. Sci. USA 92, 9141–9145.
[8] Wilhelmsen, K.C., Forman, M.S., Rosen, H.J., Alving, L.I., Goldman, J., Feiger, J.,
Lee, J.V., Segall, S.K., Kramer, J.H., Lomen-Hoerth, C., Rankin, K.P., Johnson, J.,
Feiler, H.S., Weiner, M.W., Lee, V.M., Trojanowski, J.Q. and Miller, B.L. (2004)
17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without
tau mutations with tau and alpha-synuclein inclusions. Arch. Neurol. 61,
398–406.
[9] Hamilton, R.L. (2000) Lewy bodies in Alzheimer’s disease: a neuropathological
review of 145 cases using alpha-synuclein immunohistochemistry. Brain
Pathol. 10, 378–384.
[10] Raghavan, R., Khin-Nu, C., Brown, A., Irving, D., Ince, P.G., Day, K., Tyrer, S.P.
and Perry, R.H. (1993) Detection of Lewy bodies in Trisomy 21 (Down’s
syndrome). Can. J. Neurol. Sci. 20, 48–51.
[11] Judkins, A.R., Forman, M.S., Uryu, K., Hinkle, D.A., Asbury, A.K., Lee, V.M. and
Trojanowski, J.Q. (2002) Co-occurrence of Parkinson’s disease with progressive
supranuclear palsy. Acta Neuropathol. 103, 526–530.
[12] Galpern, W.R. and Lang, A.E. (2006) Interface between tauopathies and
synucleinopathies: a tale of two proteins. Ann. Neurol. 59, 449–458.
[13] Clarimon, J., Molina-Porcel, L., Gomez-Isla, T., Blesa, R., Guardia-Laguarta, C.,
Gonzalez-Neira, A., Estorch, M., Ma, G.J., Barraquer, L., Roig, C., Ferrer, I. and
Lleo, A. (2009) Early-onset familial lewy body dementia with extensive
tauopathy: a clinical, genetic, and neuropathological study. J. Neuropathol.
Exp. Neurol. 68, 73–82.
[14] Galloway, P.G., Grundke-Iqbal, I., Iqbal, K. and Perry, G. (1988) Lewy bodies
contain epitopes both shared and distinct from Alzheimer neuroﬁbrillary
tangles. J. Neuropathol. Exp. Neurol. 47, 654–663.
[15] Giasson, B.I., Forman, M.S., Higuchi, M., Golbe, L.I., Graves, C.L., Kotzbauer, P.T.,
Trojanowski, J.Q. and Lee, V.M. (2003) Initiation and synergistic ﬁbrillization
of tau and alpha-synuclein. Science 300, 636–640.
[16] Ishizawa, T., Mattila, P., Davies, P., Wang, D. and Dickson, D.W. (2003)
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J.
Neuropathol. Exp. Neurol. 62, 389–397.
[17] Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J.N. and Sidhu, A. (2010)
Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s
disease brains with and without dementia. Exp. Neurol. 225, 210–218.
[18] Haggerty, T., Credle, J., Rodriguez, O., Wills, J., Oaks, A.W., Masliah, E. and
Sidhu, A. (2011) Hyperphosphorylated Tau in an alpha-synuclein-
overexpressing transgenic model of Parkinson’s disease. Eur. J. Neurosci. 33,
1598–1610.
12 F. Herrera, T.F. Outeiro / FEBS Letters 586 (2012) 7–12[19] Badiola, N., de Oliveira, R.M., Herrera, F., Guardia-Laguarta, C., Gonçalves, S.A.,
Pera, M., Suarez-Calvet, M., Clarimon, J., Outeiro, T.F. and Lleó, A. (2011) Tau
enhances a-Synuclein aggregation and toxicity in cellular models of
synucleinopathy. PLoS One 6, e26609.
[20] Masliah, E., Iwai, A., Mallory, M., Ueda, K. and Saitoh, T. (1996) Altered
presynaptic protein NACP is associated with plaque formation and
neurodegeneration in Alzheimer’s disease. Am. J. Pathol. 148, 201–210.
[21] Clinton, L.K., Blurton-Jones, M., Myczek, K., Trojanowski, J.Q. and LaFerla, F.M.
(2010) Synergistic Interactions between Abeta, tau, and alpha-synuclein:
acceleration of neuropathology and cognitive decline. J. Neurosci. 30,
7281–7289.
[22] Charles, V.,Mezey, E., Reddy, P.H.,Dehejia,A., Young, T.A., Polymeropoulos,M.H.,
Brownstein, M.J. and Tagle, D.A. (2000) Alpha-synuclein immunoreactivity of
huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s
disease patients and transgenic mouse models. Neurosci. Lett. 289, 29–32.
[23] Furlong, R.A., Narain, Y., Rankin, J., Wyttenbach, A. and Rubinsztein, D.C.
(2000) Alpha-synuclein overexpression promotes aggregation of mutant
huntingtin. Biochem. J. 346 (3), 577–581.
[24] Herrera, F., Tenreiro, S., Miller-Fleming, L. and Outeiro, T.F. (2011)
Visualization of cell-to-cell transmission of mutant huntingtin oligomers.
PLoS Curr. 3, RRN1210.[25] Outeiro, T.F., Putcha, P., Tetzlaff, J.E., Spoelgen, R., Koker, M., Carvalho, F.,
Hyman, B.T. and McLean, P.J. (2008) Formation of toxic oligomeric alpha-
synuclein species in living cells. PLoS One 3, e1867.
[26] Outeiro, T.F. and Lindquist, S. (2003) Yeast cells provide insight into alpha-
synuclein biology and pathobiology. Science 302, 1772–1775.
[27] Krobitsch, S. and Lindquist, S. (2000) Aggregation of huntingtin in yeast varies
with the length of the polyglutamine expansion and the expression of
chaperone proteins. Proc. Natl. Acad. Sci. USA 97, 1589–1594.
[28] Herrera, F., Chen, Q., Fishcer, W.H., Maher, P. and Schubert, D.R. (2009)
Synaptojanin-1 plays a key role in astrogliogenesis: possible relevance for
Down’s syndrome. Cell Death Differ. 16, 910–920.
[29] Yan, Y., Peng, D., Tian, J., Chi, J., Tan, J., Yin, X., Pu, J., Xia, K. and Zhang, B. (2011)
Essential sequence of the N-terminal cytoplasmic localization-related domain
of Huntingtin and its effect on Huntingtin aggregates. Sci. China Life Sci. 54,
342–350.
[30] Lippa, C.F., Fujiwara, H., Mann, D.M., Giasson, B., Baba, M., Schmidt, M.L., Nee,
L.E., O’Connell, B., Pollen, D.A., St George-Hyslop, P., Ghetti, B., Nochlin, D., Bird,
T.D., Cairns, N.J., Lee, V.M., Iwatsubo, T. and Trojanowski, J.Q. (1998) Lewy
bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s
disease patients with mutations in presenilin and amyloid precursor protein
genes. Am. J. Pathol. 153, 1365–1370.
